Compare Infosys Limited (INFY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs TransMedics Group Inc — how do they compare? Infosys Limited trades at $12.24 (market cap $50.55B), while TransMedics Group Inc trades at $87.29 (market cap $3.10B). The key difference: Infosys Limited is far larger — about 16.3× TransMedics Group Inc's market cap, and Infosys Limited pays a 4.16% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| INFY | TMDX | |
|---|---|---|
Market Cap | $50.55B | $3.10B |
Sector | Technology | Technology |
52-Week High | $20.22 | $150.42 |
52-Week Low | $10.49 | $61.99 |
Enterprise Value | $48.30B | $3.49B |
Dividend Yield | 4.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.215, down 2.75% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators including RSI above 76. Fundamentally, the company maintains strong profitability with 16.37% net margins and 32.12% ROE, though Q2 2026 earnings missed expectations. Recent news highlights strategic AI collaborations with Metsä Group and Sentara Healthcare while Q1 2027 results showed revenue challenges but margin resilience.
The outlook remains cautious with analyst consensus at Hold (55%) and $11.05 price target below current levels. Key opportunities include growing AI revenue streams and strong cash flow generation, while risks involve revenue growth volatility and competitive IT services market pressures. The stock faces near-term headwinds from lowered growth guidance but maintains solid fundamentals.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
